CN111163791A - 预测对fgf-18化合物反应性的代谢生物标志物 - Google Patents

预测对fgf-18化合物反应性的代谢生物标志物 Download PDF

Info

Publication number
CN111163791A
CN111163791A CN201880063185.7A CN201880063185A CN111163791A CN 111163791 A CN111163791 A CN 111163791A CN 201880063185 A CN201880063185 A CN 201880063185A CN 111163791 A CN111163791 A CN 111163791A
Authority
CN
China
Prior art keywords
fgf
treatment
compound
cartilage
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880063185.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·H·雷德尔
H·焦耳林
A-C·拜杰森
M·卡斯戴尔
P·奎斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CN111163791A publication Critical patent/CN111163791A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201880063185.7A 2017-09-29 2018-09-28 预测对fgf-18化合物反应性的代谢生物标志物 Pending CN111163791A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17194220.4 2017-09-29
EP17194220 2017-09-29
EP18169324 2018-04-25
EP18169324.3 2018-04-25
PCT/EP2018/076395 WO2019063758A1 (en) 2017-09-29 2018-09-28 METABOLIC BIOMARKERS FOR PREDICTING RESPONSE TO FGF-18 COMPOUND

Publications (1)

Publication Number Publication Date
CN111163791A true CN111163791A (zh) 2020-05-15

Family

ID=63722380

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880063185.7A Pending CN111163791A (zh) 2017-09-29 2018-09-28 预测对fgf-18化合物反应性的代谢生物标志物

Country Status (16)

Country Link
US (2) US11513128B2 (https=)
EP (1) EP3687558B1 (https=)
JP (2) JP7791649B2 (https=)
CN (1) CN111163791A (https=)
AU (1) AU2018343982B2 (https=)
CA (1) CA3076029A1 (https=)
DK (1) DK3687558T3 (https=)
ES (1) ES2918250T3 (https=)
HR (1) HRP20220760T1 (https=)
HU (1) HUE058786T2 (https=)
IL (1) IL273613B2 (https=)
LT (1) LT3687558T (https=)
PL (1) PL3687558T3 (https=)
RS (1) RS63293B1 (https=)
SI (1) SI3687558T1 (https=)
WO (1) WO2019063758A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
IL273613B2 (en) 2017-09-29 2026-02-01 Merck Patent Gmbh Metabolic biomarkers for predicting response to FGF-18 compound
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292892A1 (en) * 2002-11-08 2007-12-20 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
WO2008023063A2 (en) * 2006-08-25 2008-02-28 Ares Trading S.A. Treatment of cartilage disorders with fgf-18
JP2009257842A (ja) * 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
CN104736723A (zh) * 2012-08-06 2015-06-24 默克专利有限公司 用于预测对fgf-18化合物的响应性的遗传标记
US20160154008A1 (en) * 2013-07-15 2016-06-02 Steven J. Svoboda Methods and apparatus for assessment of risk for joint injury
WO2019063758A1 (en) * 2017-09-29 2019-04-04 Merck Patent Gmbh METABOLIC BIOMARKERS FOR PREDICTING RESPONSE TO FGF-18 COMPOUND

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2339002A1 (en) 1996-10-16 2011-06-29 ZymoGenetics, Inc. Fibroblast growth factor homologs
ES2493840T3 (es) 2002-10-07 2014-09-12 Zymogenetics, Inc. Procedimiento de administración de FGF-18
AU2005314438B2 (en) 2004-12-10 2012-03-29 Zymogenetics, Inc. FGF18 production in prokaryotic hosts
US8224579B2 (en) * 2005-06-17 2012-07-17 The Brigham And Women's Hospital, Inc. Method of diagnosing osteoarthritis
US20070292982A1 (en) 2006-06-16 2007-12-20 Jeffery Gail Holloway Method for Manufacturing Transparent Windows in Molded Semiconductor Packages
JP5762282B2 (ja) 2008-05-02 2015-08-12 インタールーキン ジェネティクス， インコーポレイテッド 変形性関節症に関連する状態に対する遺伝的素因の検出
US20090299769A1 (en) 2008-05-29 2009-12-03 Nordic Bioscience Imaging A/S Prognostic osteoarthritis biomarkers
US20120115137A1 (en) 2010-08-31 2012-05-10 Kornman Kenneth S Methods of Predicting Osteoarthritis
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
AU2013301607B2 (en) 2012-08-06 2018-10-18 Merck Patent Gmbh Prognosis biomarkers in cartilage disorders
CA2931978A1 (en) 2013-12-02 2015-06-11 Abbvie Inc. Compositions and methods for treating osteoarthritis
ES2806026T3 (es) 2013-12-24 2021-02-16 Ares Trading Sa Formulación de FGF-18 en hidrogeles de alginato/colágeno
KR102622290B1 (ko) 2013-12-24 2024-01-05 아레스 트레이딩 에스.아. 크실로글루칸 겔 중의 fgf-18 제형물
HUE040350T2 (hu) 2014-02-20 2019-03-28 Merck Patent Gmbh FGF-18 vegyületadagoló étrend
MX2016010873A (es) 2014-02-20 2016-11-17 Merck Patent Gmbh Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos.
JP6510547B2 (ja) 2014-02-20 2019-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｇｆ−１８を含むインプラント
AU2016211950A1 (en) 2015-01-29 2017-07-13 Ares Trading S.A. Immunoassays for high positively charged proteins
MX380092B (es) 2015-11-06 2025-03-11 Samumed Llc Tratamiento de la osteoartritis.
US9983214B2 (en) 2016-04-15 2018-05-29 Esm Technologies, Llc Method for evaluating articular joint therapeutics
SI3688468T1 (sl) 2017-09-29 2022-08-31 Merck Patent Gmbh Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292892A1 (en) * 2002-11-08 2007-12-20 Barnes-Jewish Hospital Uncoupled collagen synthesis and degradation assays
WO2008023063A2 (en) * 2006-08-25 2008-02-28 Ares Trading S.A. Treatment of cartilage disorders with fgf-18
JP2009257842A (ja) * 2008-04-14 2009-11-05 Ttc:Kk 変形性関節症の検査方法及び診断用キット
CN104736723A (zh) * 2012-08-06 2015-06-24 默克专利有限公司 用于预测对fgf-18化合物的响应性的遗传标记
US20160154008A1 (en) * 2013-07-15 2016-06-02 Steven J. Svoboda Methods and apparatus for assessment of risk for joint injury
WO2019063758A1 (en) * 2017-09-29 2019-04-04 Merck Patent Gmbh METABOLIC BIOMARKERS FOR PREDICTING RESPONSE TO FGF-18 COMPOUND

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
A C BAY-JENSEN ET AL.: "Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria", 《OSTEOARTHRITIS CARTILAGE》 *
A.C.BAY-JENSEN ET AL.: "Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study", 《OSTEOARTHRITIS AND CARTILAGE》 *
B HUA ET AL.: "Serological biomarkers detect active joint destruction and inflammation in patients with haemophilic arthropathy", 《HAEMOPHILIA》 *
GÜHRING H ET AL.: "RI0404 SEPERATION OF HIGH AND LOW RESPONSE GROUPS IN OSTEOARTHRITIS USING SERUM CARTILAGE DEGRADATION AND FORMATION MARKERS – A 3 YEAR FOLLOW-UP ON THE FORWARD STUDY TESTING THE EFFICACY OF SPRIFERMIN", 《ANNALS OF THE RHEUMATIC DISEASES》 *
M E DUCLOS ET AL.: "Significance of the serum CTX-II level in an osteoarthritis animal model: a 5-month longitudinal study", 《OSTEOARTHRITIS CARTILAGE》 *
NATASJA STÆHR GUDMANN ET AL.: "Cartilage turnover reflected by metabolic processing of type II collagen: a novel marker of anabolic function in chondrocytes", 《INT J MOL SCI》 *
NATASJA STÆHR GUDMANN ET AL.: "Chondrocyte activity is increased in psoriatic arthritis and axial spondyloarthritis", 《ARTHRITIS RES THER》 *
SPRIFERMIN PHASE II TRIAL OF SPRIFERMIN IN KNEE OA EMR700692_006: "Clinical Trial Protocol", 《HTTPS://CLINICALTRIALS.GOV/PROVIDEDDOCS/64/NCT01919164/PROT_000.PDF》 *
YUNYUN LUO ET AL.: "A low cartilage formation and repair endotype predicts radiographic progression of symptomatic knee osteoarthritis", 《JOURNAL OF ORTHOPAEDICS AND TRAUMATOLOGY》 *
刘忠厚主编: "《骨矿与临床》", 31 March 2006, 中国科学技术出版社 *

Also Published As

Publication number Publication date
EP3687558A1 (en) 2020-08-05
JP2020535436A (ja) 2020-12-03
US12332251B2 (en) 2025-06-17
AU2018343982A1 (en) 2020-04-09
US20230251271A1 (en) 2023-08-10
HUE058786T2 (hu) 2022-09-28
US20210231681A1 (en) 2021-07-29
LT3687558T (lt) 2022-06-27
JP7791649B2 (ja) 2025-12-24
WO2019063758A1 (en) 2019-04-04
AU2018343982B2 (en) 2025-03-27
EP3687558B1 (en) 2022-03-16
DK3687558T3 (da) 2022-06-20
PL3687558T3 (pl) 2022-07-18
RS63293B1 (sr) 2022-06-30
ES2918250T3 (es) 2022-07-14
JP2024105273A (ja) 2024-08-06
HRP20220760T1 (hr) 2022-09-02
IL273613A (en) 2020-05-31
CA3076029A1 (en) 2019-04-04
IL273613B2 (en) 2026-02-01
US11513128B2 (en) 2022-11-29
SI3687558T1 (sl) 2022-08-31
IL273613B1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
US12332251B2 (en) Metabolic biomarkers for predicting responsiveness to FGF-18 compound
US12332250B2 (en) Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
JP7568614B2 (ja) 変形性関節症の治療のための富化戦略において有用なマーカー
HK40058829A (en) Markers useful in enrichment strategies for the treatment of osteoarthritis
HK40058829B (en) Markers useful in enrichment strategies for the treatment of osteoarthritis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination